Skip to content

PharmaSi

Active Private limited companyfounded 2018active for 8 yearsVrijthof 9, 3630 MaasmechelenKBO/BCE: BE 0687.947.061

Lifetime

8 annual accounts with figures on one time axis
peak of €56,751 in 2021
€44,166▲ 23.9%
peak of €39,394 in 2021
€23,327▲ 37.7%
peak of €117,015 in 2023
€52,289▼ 37.7%
€6,306▼ 13.9%
Board1 name since 2018
- 
Documentsfilings and deeds
25-08-202625 days late
2025micro format
Gross margin from €35,650 to €44,166Result from €16,947 to €23,327Dividend €55,000Equity from €83,962 to €52,289Cash from €35,977 to €49,335

Key points

from the 2025 annual accounts

Equity

€52,289 ▼ 37.7%
83,9622024+23,327Profit-55,000Dividend52,2892025

PharmaSi paid out €55,000 in dividends. That is 236% of the 2025 profit.

Filings

8 annual accounts 5 late
AprilJune31 JulyOctober20202025

The 2024 accounts came in latest, 50 days after the end of the period.

Position in the sector

89.2%

Higher solvency than 93% of companies in retail trade. Sector median 33.3% · 25,338 companies.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 26,977 companies had the same profile as PharmaSi has now. Each dot stands for 68 companies, two years later.

94.8%
were still trading
3.5%
stopped another way
1.6%
went bankrupt
  • Micro
  • 5 to 10 years old
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more

Another 0.1% stopped without a precise date, possibly only after those two years.

Test of the method

The method was tested on the 497,962 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 26,977 companies, not a prediction for PharmaSi. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

last known board
Director, until 2024
  • 186 sharesdeed of 17-01-2018
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0687947061
changes role from manager to director “zie purpose” (deed in Dutch) · General meeting of 09-01-2024 · Gazette deed
Incorporation appointed as manager · Founder: · Founding capital of €18,600, 186 shares · published on 17-01-2018 · Gazette deed
First establishment Vrijthof 9, Maasmechelen
All 15 events

Comparable companies

same main activity, similar in size and age
Company
PharmaSi Maasmechelen €58,595 €44,166 89.2% -
SoBayFRo Tournai €54,756 €41,082 30.9% -
MBV Consult Lier €63,750 €50,772 1.6% -
VANFLETEREN PIETER Antwerp €52,894 €36,548 69.8% -
AKV PHARMA Pittem €58,563 €40,416 89.5% -
NIEMEGEERS KAROLIEN Bonheiden €61,719 €36,058 30.1% -
KameleonPharma Wellen €70,327 €31,928 81.4% -

These companies have the same main activity as PharmaSi: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €52,900 and €70,300, founded between 2015 and 2018.

Official details

Source: KBO
Status
Active since 15-01-2018Normal situation
Activity
Retail sale of pharmaceutical productsNACE 47730and 1 other
Establishment unit
2.271.724.1623630 Maasmechelen, since 15-01-2018
Financial year end
31 December
Peppol
Reachable since 04-07-2025
Company details

Annual accounts 2025

≈ €200,000estimated
€58,595▼ 35.8%
Filing
Filed on 25-08-2026
Financials

Insights on PharmaSi

PharmaSi files the micro format. That format states no turnover. The gross margin rose from €21,079 in 2018 to €44,166 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about PharmaSi

What is the company number of PharmaSi?
The company number of PharmaSi is 0687.947.061. The VAT number is the same number with BE in front: BE 0687.947.061.
Where is PharmaSi based?
The registered office is at Vrijthof 9, 3630 Maasmechelen.Company details
What does PharmaSi do?
According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
What is the legal form of PharmaSi?
PharmaSi is a private limited company (BV).
When was PharmaSi founded?
PharmaSi was founded on 15-01-2018.
Is PharmaSi still active?
Yes, PharmaSi is an active enterprise in the KBO register.
What is the turnover of PharmaSi?
The turnover in financial year 2025 is ≈ €200,000. This figure is estimated from the gross margin of €44,166 and 56 comparable companies (NACE 477). It probably lies between €110,000 and €360,000.Financials
Is PharmaSi profitable?
In financial year 2025, PharmaSi made a profit of €23,327.
Where can I find the annual accounts of PharmaSi?
PharmaSi filed 8 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of PharmaSi due?
PharmaSi must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.